Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) saw a significant increase in short interest in May. As of May 29th, there was short interest totaling 310 shares, an increase of 3,344.4% from the May 14th total of 9 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 2,834 shares, the short-interest ratio is presently 0.1 days.

Enzon Pharmaceuticals Stock Performance

Shares of Enzon Pharmaceuticals stock opened at $5.75 on Thursday. The firm has a market cap of $4.26 million, a price-to-earnings ratio of -0.84 and a beta of -0.06. The stock’s 50-day moving average is $6.03 and its 200-day moving average is $5.58. Enzon Pharmaceuticals has a one year low of $1.50 and a one year high of $12.99. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.01 and a quick ratio of 1.16.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last released its earnings results on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share for the quarter. The company had revenue of $86.54 million for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.